https://nationlife.net/enjoy-eating-without-the-fear-of-choking-with-lifevac-review/
LifeVac is a patented life-saving device that is proven to be the most effective way to help a child or adult during a choking emergency.
Place LifeVac over the mouth and nose to create a seal. The one-way valve prevents air from pushing food or objects downward when pressed. Then simply pull to create a one-way suction to remove the lodged food or object in seconds.
LifeVac gives you peace of mind knowing you’re always prepared and your loved ones are protected – because every second matter.
Recommended by hundreds of doctors and medical professionals around the world. Over 100,000 sold in over 40 countries and counting!
Is your life or your child’s life, worth LESS than 100 bucks to you? This product is absolutely worth every penny. And I’ll be still very happy to have bought it, even if I don’t ever get to use it. I know it is there if I ever need it. This thing is absolutely fantastic. I’ve practiced a few times and from what I saw, it can very well save a life, in those critical few minutes you have, before the person becomes so deprived from oxygen and ultimately dies. Very easy to use. I’m grateful for it.
Always Be Prepared. Get LifeVac Today.
Inspire Medical Systems, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Inspire Upper Airway Stimulation (UAS) therapy for use in a subset of patients with moderate to severe Obstructive Sleep Apnea (OSA) who are unable to use Continuous Positive Airway Pressure (CPAP). Inspire therapy is a fully implanted neurostimulation device, the first of its kind for sleep apnea, that provides an alternative treatment that is proven, convenient and easy to use.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7169651-fda-approves-inspire-upper-airway-stimulation-therapy-sleep-apnea
Thirty-six million Americans suffer from migraines, leading to more than $20 billion in medical expenses and costs related to lost productivity each year¹. In recognition of National Migraine Awareness Month and the significant unmet medical needs of migraine patients, Zogenix, Inc. (NASDAQ: ZGNX) is highlighting the importance of selecting the appropriate medication for a patient’s “treatment toolbox” to address specific types of migraine episodes.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/zogenix/50344/
“Explore Your Treatment Options,” a new multimedia ad campaign announced today by the U.S. Department of Health and Human Services’ Agency for Healthcare Research and Quality (AHRQ) and the Ad Council, encourages patients to become more informed about their options before choosing a treatment for a health condition or illness.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/adcouncil/50583/
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
The Center For Aesthetics
https://thecenterforaesthetics.com
800-575-8337 ~ The CFA Exclusive Evernal Series - Complexion Perfection, laser skincare and hydrafacials. CFA Beauty the premier aesthetic medical centers in Scottsdale, Jackson Hole, Idaho Falls.
Ethicon*, a trusted leader in advancing wound closure, announces the launch of STRATAFIX™ Spiral PDS Plus and STRATAFIX™ Spiral Monocryl Plus Knotless Tissue Control Devices. With the addition of these two new suture technologies to the STRATAFIX™ Family of Knotless Tissue Control Devices, Ethicon has established the most comprehensive and unmatched knotless suture offering available to surgeons in the U.S.
STRATAFIX™ Knotless Tissue Control Devices transforms the wound closure experience by providing unique advantages over traditional sutures. STRATAFIX™ sutures provide more strength and security, more consistency and more efficiency than traditional suturing. The portfolio of knotless sutures also enables surgeons to more easily manage tension and control tissue approximation with each pass during closure and eliminates the need to tie knots.
To view the multimedia release go to:
http://www.multivu.com/players/English/7889651-ethicon-new-stratafix-suture/
Ethicon, Inc., a worldwide leader in surgical care, has announced its entrance into the barbed suture market with the launch of its new portfolio of STRATAFIX™ Knotless Tissue Control Devices, representing the next evolution in wound closure technology. With significantly more points of fixation than traditional sutures, STRATAFIX™ Devices give surgeons more consistent control over every pass (through the tissue), and combine the strength and security of interrupted closure with the efficiency of continuous closure.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58405-ethicon-launches-stratafix-knotless-tissue-control-devices
The truly ergonomic HandShoe Mouse has been designed to stop pinching and gripping like you do with a standard computer mouse. Gripping and Pinching is a major cause for Repetitive Strain Injury RSI) and Carpal Tunnel Syndrome.
This ergonomic mouse (the HandShoe mouse) also prevents that your fingers are hovering above the mouse buttons, another cause for RSI and capral tunnel syndrome. The HandShoe mouse has been developed by a medical university and has been tested in large organizations for almost two years.
Upsher-Smith Laboratories, Inc. [http://www.upsher-smith.com] today announced that subscribers to Epilog.us can now access the latest information related to Practice Management & Epilepsy at http://www.Epilog.us. Led by Dr. Aatif Husain, Director of the Clinical Neurophysiology Fellowship, Professor of Medicine, Division of Neurology, Duke University Medical Center, and Dr. John Stern, Co‐Director of the Seizure Disorder Center and Professor of Neurology at the David Geffen School of Medicine at UCLA, areas of focus include: the importance of billing code accuracy; commonly utilized billing codes in epilepsy and neurology; and epilepsy quality measures from the American Academy of Neurology (AAN).
To view Multimedia News Release, go to http://www.multivu.com/mnr/58062-upsher-smith-epilog-us-practice-management-epilepsy-resources-available
Dentro de las más de 50 propuestas de estudios de investigación, el estudio sobre ácidos grasos de omega 3 en pacientes hospitalizados que requieren nutrición parenteral y presentan complicaciones relacionadas con insuficiencias intestinales propuesto por la investigadora médica, la Dra. Aurora Serralde Zúñiga, ganó el primer subsidio para la investigación sobre nutrición parenteral en América Latina (Parenteral Nutrition Research Grant Latin America).
To view the multimedia release go to:
https://www.multivu.com/players/Spanish/8451051-ganadora-del-subsidio-fresenius-kabi/
“We are all a heartbeat away from needing emergency care” is one of key messages of the Saving Millions campaign of the American College of Emergency Physicians (ACEP), highlighting the incredible value of emergency medicine to every community and the efficiency and economic benefits of medical care provided in the nation’s emergency departments. http://www.acep.org/savingmillions.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7253451-american-college-of-emergency-physicians-saving-millions-campaign/
